目的探讨血清孕酮（P）、血β-人绒毛膜促性腺激素（β-HCG）、促甲状腺激素（TSH）联合检测在预测早期妊娠结局中的临床价值。方法回顾性分析2013年12月-2015年5月在山西医学科学院就诊的100例正常妊娠患者（正常妊娠组）、80例继续妊...目的探讨血清孕酮（P）、血β-人绒毛膜促性腺激素（β-HCG）、促甲状腺激素（TSH）联合检测在预测早期妊娠结局中的临床价值。方法回顾性分析2013年12月-2015年5月在山西医学科学院就诊的100例正常妊娠患者（正常妊娠组）、80例继续妊娠患者（继续妊娠组）和80例难免流产患者（难免流产组）,采用美国贝克曼公司的DXI800化学发光免疫分析仪及配套试剂测定三组患者血清中的P、β-HCG、TSH值。结果 P、β-HCG、TSH的受试者工作特征曲线（ROC）下面积分别为0.702、0.776、0.468,联合检测的ROC曲线下面积为0.999。血清P、β-HCG、TSH预测活胎与难免流产的cut-off值分别为12.90 ng/ml、10 258 m IU/ml、2.5 m IU/L。将各项激素的cut-off值设定为临界值,得出难免流产组的P、β-HCG水平显著低于正常妊娠组和继续妊娠组,阳性率高于正常妊娠组和继续妊娠组,TSH水平和阳性率均显著高于正常妊娠组和继续妊娠组（P均〈0.05）;3项激素中,β-HCG的阳性率（68.00%）最高;P、β-HCG、TSH联合检测的灵敏度为68.75%,特异度为71.50%,阳性预测值为51.56%,阴性预测值为72.36%,各指标均高于单项检测（P〈0.05）。结论单项激素预测早期妊娠结局的价值不高。P、β-HCG、TSH联合检测有助于提高难免流产的诊断性能和早期检出率,3项激素联合检测是预测难免流产较理想的标志物组合。展开更多
This review describes briefly the beneficial use of two vaccines developed by us for treatment of cancers. The vaccine against Luteinizing Hormone Releasing Hormone (LHRH) is effective in carcinoma of prostate as well...This review describes briefly the beneficial use of two vaccines developed by us for treatment of cancers. The vaccine against Luteinizing Hormone Releasing Hormone (LHRH) is effective in carcinoma of prostate as well as in breast cancers dependent on androgens and estrogens respectively. LHRH being identical in both males and females, the same vaccine is usable in both Prostate and Breast steroid hormones-dependent-cancers. Monoclonal antibodies are finding therapeutic utility in several cancers, and many have received Drugs Regulatory approval. The monoclonals developed by us against hCG and against epitopes present on androgen-independent castration resistant prostate cancers are briefly recapitulated. Anti-hCG antibodies kill several cancers expressing hCG. An example is given of A549 lung carcinoma. MoAb730 and MoAb7B2G10 kill DU-145 and PC-3 androgen-independent castration resistant prostate cancer cells. Some cancers such as MOLT-4, a T-lymphoblastic leukemia, though expressing hCG are not killed by PiPP, the high affinity anti-hCG antibody. Linking the antibody to curcumin however works like a “Magic Bullet”. All MOLT-4 cells are killed by this conjugate, the antibody homes selectively to cancer cells expressing hCG to deliver curcumin which exercises the killing effect. A recombinant vaccine, hCGβ-LTB (human chorionic gonadotropin subunit β linked to B subunit of heat-labile enterotoxin of E. coli) has been made, which induces high titre bioeffective antibodies not only in BalbC, but also in other genetic strains of mice. The vaccine employs autoclaved Mycobacterium indicus pranii (MiP) as adjuvant. MiP invigorates both humoral and cell mediated immune responses against Human chorionic gonadotropin (hCG). Besides being a potent adjuvant, MiP used alone heals anogenital warts in humans and has the property of preventing and curing SP2/O Myelomas in mice.展开更多
文摘目的探讨血清孕酮（P）、血β-人绒毛膜促性腺激素（β-HCG）、促甲状腺激素（TSH）联合检测在预测早期妊娠结局中的临床价值。方法回顾性分析2013年12月-2015年5月在山西医学科学院就诊的100例正常妊娠患者（正常妊娠组）、80例继续妊娠患者（继续妊娠组）和80例难免流产患者（难免流产组）,采用美国贝克曼公司的DXI800化学发光免疫分析仪及配套试剂测定三组患者血清中的P、β-HCG、TSH值。结果 P、β-HCG、TSH的受试者工作特征曲线（ROC）下面积分别为0.702、0.776、0.468,联合检测的ROC曲线下面积为0.999。血清P、β-HCG、TSH预测活胎与难免流产的cut-off值分别为12.90 ng/ml、10 258 m IU/ml、2.5 m IU/L。将各项激素的cut-off值设定为临界值,得出难免流产组的P、β-HCG水平显著低于正常妊娠组和继续妊娠组,阳性率高于正常妊娠组和继续妊娠组,TSH水平和阳性率均显著高于正常妊娠组和继续妊娠组（P均〈0.05）;3项激素中,β-HCG的阳性率（68.00%）最高;P、β-HCG、TSH联合检测的灵敏度为68.75%,特异度为71.50%,阳性预测值为51.56%,阴性预测值为72.36%,各指标均高于单项检测（P〈0.05）。结论单项激素预测早期妊娠结局的价值不高。P、β-HCG、TSH联合检测有助于提高难免流产的诊断性能和早期检出率,3项激素联合检测是预测难免流产较理想的标志物组合。
文摘This review describes briefly the beneficial use of two vaccines developed by us for treatment of cancers. The vaccine against Luteinizing Hormone Releasing Hormone (LHRH) is effective in carcinoma of prostate as well as in breast cancers dependent on androgens and estrogens respectively. LHRH being identical in both males and females, the same vaccine is usable in both Prostate and Breast steroid hormones-dependent-cancers. Monoclonal antibodies are finding therapeutic utility in several cancers, and many have received Drugs Regulatory approval. The monoclonals developed by us against hCG and against epitopes present on androgen-independent castration resistant prostate cancers are briefly recapitulated. Anti-hCG antibodies kill several cancers expressing hCG. An example is given of A549 lung carcinoma. MoAb730 and MoAb7B2G10 kill DU-145 and PC-3 androgen-independent castration resistant prostate cancer cells. Some cancers such as MOLT-4, a T-lymphoblastic leukemia, though expressing hCG are not killed by PiPP, the high affinity anti-hCG antibody. Linking the antibody to curcumin however works like a “Magic Bullet”. All MOLT-4 cells are killed by this conjugate, the antibody homes selectively to cancer cells expressing hCG to deliver curcumin which exercises the killing effect. A recombinant vaccine, hCGβ-LTB (human chorionic gonadotropin subunit β linked to B subunit of heat-labile enterotoxin of E. coli) has been made, which induces high titre bioeffective antibodies not only in BalbC, but also in other genetic strains of mice. The vaccine employs autoclaved Mycobacterium indicus pranii (MiP) as adjuvant. MiP invigorates both humoral and cell mediated immune responses against Human chorionic gonadotropin (hCG). Besides being a potent adjuvant, MiP used alone heals anogenital warts in humans and has the property of preventing and curing SP2/O Myelomas in mice.
